Latest news from Rapha Capital Management & our portfolio companies
NexImmune Inc.
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
- Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health
- Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist
- Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products
January 4, 2021
NexImmune Inc.
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT)
December 7, 2020
Asclepix Therapeutics, Inc.
Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost ophthalmic startup’s shot for best of all worlds
Amber Tong, Editor, ENDPOINTS NEWS
June 24, 2020
Asclepix Therapeutics, Inc.
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Frank Vinluan, Editor, Xconomy
June 24, 2020
Asclepix Therapeutics, Inc.
AsclepiX Therapeutics Announces $35 Million Series A Financing
Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials
Series A financing led by the Perceptive Xontogeny Venture Fund
June 24, 2020
FIZE Medical Ltd.
Rapha Capital Management Leads Series A Financing for FIZE Medical Ltd
FIZE’s Novel Device Conquers the Last Frontier in Patient Monitoring
May 4, 2020
ControlRad, Inc.
ControlRad Adds Five People to Leadership Team
December 17, 2019